YangJLiCZhengY, et al.The Association Between High-Sensitivity C-Reactive Protein/Albumin Ratio and Cardiovascular Prognosis in Patients Undergoing Percutaneous Coronary Intervention. Angiology2022;73:818-826.
2.
ManolisAAManolisTAMelitaHMikhailidisDPManolisAS. Low serum albumin: A neglected predictor in patients with cardiovascular disease. Eur J Intern Med2022;102:24-39.
3.
WadaHDohiTMiyauchiK, et al.Independent and Combined Effects of Serum Albumin and C-Reactive Protein on Long-Term Outcomes of Patients Undergoing Percutaneous Coronary Intervention. Circ J2017;81:1293-300.
4.
HuangHYuYChenL, et al.Independent and joint effects of high-sensitivity c-reactive protein and hypoalbuminemia on long-term all-cause mortality among coronary artery disease: a prospective and multicenter cohort study. BMC Cardiovasc Disord2021;21:613.
5.
GuedeneyPClaessenBEKalkmanDN, et al.Residual Inflammatory Risk in Patients With Low LDL Cholesterol Levels Undergoing Percutaneous Coronary Intervention. J Am Coll Cardiol2019;73:2401-9.
6.
LiuZYTangJNChengMD, et al.C-reactive protein-to-serum albumin ratio as a novel predictor of long-term outcomes in coronary artery disease patients who have undergone percutaneous coronary intervention: analysis of a real-world retrospective cohort study. Coron Artery Dis2021;32:191-196.
7.
RonitAKirkegaard-KlitboDMDohlmannTL, et al.Plasma albumin and incident cardiovascular disease: results from the cgps and an updated meta-analysis. Arterioscler Thromb Vasc Biol2020;40:473-482.
8.
KalkanSCagan EfeSKaragözA, et al.A new predictor of mortality in st-elevation myocardial infarction: the uric acid albumin ratio. Angiology2022;73:461-469.
9.
AkirovAMasri-IraqiHAtamnaAShimonI. Low albumin levels are associated with mortality risk in hospitalized patients. Am J Med2017;130:1465.e11-1465.e19.
10.
TurkyilmazEOzkalayciFBirdalO, et al.Serum Albumin to Creatinine Ratio and Short-Term Clinical Outcomes in Patients With ST-Elevation Myocardial Infarction. Angiology2022;73:809-817.
11.
ManolisASManolisTAMelitaH. Atherosclerosis: an Athero-Thrombo-Inflammatory Disease. Hosp Chronicles2012;7: 195-201.
12.
DumanHÇinierGBakırcıEM, et al.Relationship Between C-Reactive Protein to Albumin Ratio and Thrombus Burden in Patients With Acute Coronary Syndrome. Clin Appl Thromb Hemost2019;25:1076029618824418.
13.
RidkerPMEverettBMThurenT, et al.Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med2017;377:1119-31.
14.
KauraAHartleyAPanoulasV, et al.Mortality risk prediction of high-sensitivity C-reactive protein in suspected acute coronary syndrome: A cohort study. PLoS Med2022;19:e1003911.
15.
AndreottiFMaggioniAPCampeggiAIervolinoAScambiaGMassettiM. Anti-inflammatory therapy in ischaemic heart disease: from canakinumab to colchicine. Eur Heart J Suppl2021;23:E13-E18.
16.
SunMDubéMPHennessyT, et al.Low-dose colchicine and high-sensitivity C-reactive protein after myocardial infarction: A combined analysis using individual patient data from the COLCOT and LoDoCo-MI studies. Int J Cardiol2022;363:20-2.
17.
RidkerPMEverettBMPradhanA, et al.Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. N Engl J Med2019;380:752-62.
